T Rowe Price Equity Income Fund's Q1 2026 Investment Moves
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 14 hours ago
0mins
Should l Buy AZN?
Source: Yahoo Finance
- New Stock Additions: In Q1 2026, T Rowe Price Equity Income Fund added a total of 8 stocks, with AstraZeneca PLC (NYSE:AZN) being the largest addition at 665,000 shares valued at $131.15 million, representing 0.83% of the portfolio, indicating confidence in the biopharmaceutical sector.
- Key Position Increases: The fund increased stakes in 37 stocks, notably Rayonier Inc (NYSE:RYN) with an additional 3,090,285 shares, a 92.64% increase, bringing total holdings to 6,426,000 shares, reflecting optimism in the forestry and real estate markets.
- Complete Exits: The fund completely exited 8 holdings in Q1 2026, including AstraZeneca PLC (NYSE:AZN) and Cummins Inc (NYSE:CMI), resulting in a -0.77% and -0.24% impact on the portfolio respectively, indicating a reassessment of these companies' prospects.
- Significant Reductions: The fund reduced positions in 78 stocks, particularly cutting Accenture PLC (NYSE:ACN) by 216,000 shares, a 53.33% decrease, reflecting a cautious outlook on its future performance, especially as the stock has returned -29.15% over the past three months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AZN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise
14 Analyst Rating
13 Buy
0 Hold
1 Sell
Strong Buy
Current: 200.690
Low
157.61
Averages
213.64
High
252.18
Current: 200.690
Low
157.61
Averages
213.64
High
252.18
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
T Rowe Price Equity Income Fund's Q1 2026 Investment Moves
- New Stock Additions: In Q1 2026, T Rowe Price Equity Income Fund added a total of 8 stocks, with AstraZeneca PLC (NYSE:AZN) being the largest addition at 665,000 shares valued at $131.15 million, representing 0.83% of the portfolio, indicating confidence in the biopharmaceutical sector.
- Key Position Increases: The fund increased stakes in 37 stocks, notably Rayonier Inc (NYSE:RYN) with an additional 3,090,285 shares, a 92.64% increase, bringing total holdings to 6,426,000 shares, reflecting optimism in the forestry and real estate markets.
- Complete Exits: The fund completely exited 8 holdings in Q1 2026, including AstraZeneca PLC (NYSE:AZN) and Cummins Inc (NYSE:CMI), resulting in a -0.77% and -0.24% impact on the portfolio respectively, indicating a reassessment of these companies' prospects.
- Significant Reductions: The fund reduced positions in 78 stocks, particularly cutting Accenture PLC (NYSE:ACN) by 216,000 shares, a 53.33% decrease, reflecting a cautious outlook on its future performance, especially as the stock has returned -29.15% over the past three months.
See More
AstraZeneca Seeks Accelerated Approval for Ultomiris
- Clinical Trial Success: AstraZeneca's Ultomiris demonstrated a statistically significant and clinically meaningful reduction in proteinuria at Week 34 in the I CAN Phase III trial for IgAN patients, indicating strong potential for treating rare diseases.
- Patient Recruitment Plan: The global trial aims to enroll nearly 510 IgAN patients to assess Ultomiris as a late-line treatment, with successful preliminary results providing robust support for accelerated approval.
- Safety Assessment: The trial results indicated no new safety signals, and Ultomiris's intravenous therapy showed a tolerability profile consistent with prior data, enhancing its competitive position in the market.
- Future Outlook: AstraZeneca plans to file data with regulatory authorities in key regions while continuing the I CAN trial, with results for another primary endpoint expected at Week 106, demonstrating the company's ongoing commitment to the rare disease sector.
See More
AstraZeneca's Antibody Therapy Achieves Late-Stage Trial Success
- Trial Success: AstraZeneca announced a successful late-stage trial of its antibody therapy tozorakimab in the Phase 3 MIRANDA trial for chronic obstructive pulmonary disease (COPD), significantly reducing the annualized rate of moderate-to-severe exacerbations with both statistical and clinical significance.
- Broad Applicability: The therapy demonstrated efficacy across both former and current smokers, indicating its effectiveness regardless of lung function severity and blood eosinophil counts, thereby enhancing its market potential.
- Study Design: The 52-week study evaluated tozorakimab 300 mg administered biweekly against a placebo, aiming to assess its additional efficacy on top of standard inhaled therapy, further validating its clinical application value.
- Favorable Safety Profile: AstraZeneca noted that tozorakimab was generally well tolerated with a safety profile consistent with prior trials, and plans to submit the results to global regulators and present them at future medical events, facilitating its market introduction.
See More
AstraZeneca's IL-33-targeting Biologic Achieves Success in Phase III Trials
- Clinical Trial Results: AstraZeneca's IL-33-targeting biologic tozorakimab demonstrated significant efficacy in the Phase III MIRANDA trial, showing a meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations, particularly among former smokers, indicating its potential first-in-class status in COPD treatment.
- Patient Recruitment: The MIRANDA trial enrolled 1,454 patients, all of whom received tozorakimab 300mg alongside standard care, with results highlighting the drug's important clinical benefits for patients still experiencing exacerbations, thus addressing a critical need in COPD management.
- Safety Profile: Tozorakimab was generally well tolerated with a favorable safety profile consistent with previous trials, providing strong support for its future regulatory approval and the potential to offer new treatment options for COPD patients.
- Market Potential: With COPD being the third leading cause of death globally, affecting nearly 400 million people, the success of tozorakimab could significantly enhance patient quality of life and further bolster AstraZeneca's leadership position in the respiratory therapeutics market.
See More
Pictet North America Advisors Increases Stake in MercadoLibre
- Share Increase: On April 14, 2026, Pictet North America Advisors SA disclosed an increase of 3,529 shares in MercadoLibre, with an estimated transaction value of $6.81 million, indicating confidence in the company's future growth prospects.
- Stake Growth: Following this purchase, Pictet's stake in MercadoLibre rose to 2.21%, reflecting its emphasis on the company within its portfolio, particularly as MercadoLibre's market capitalization reached $92.87 billion.
- Financial Performance: Despite achieving a 44% revenue growth in 2025, MercadoLibre's net income only increased by 5% due to heightened competition and rising non-performing loans, indicating some profitability pressures.
- Market Outlook: Although facing short-term challenges, MercadoLibre is expected to maintain long-term growth potential due to its market leadership in Latin America and robust revenue growth, suggesting that Pictet's decision to increase its holdings may be based on confidence in this outlook.
See More
AbbVie Ventures into Weight Loss Market with Promising Drug
- Clinical Trial Results: AbbVie's March 9 announcement of ABBV-295's clinical trial results indicates that patients receiving weekly treatment lost an average of 7.75% to 9.79% of their weight over 12 weeks, while those on biweekly or monthly regimens lost between 7.86% and 9.73% over 13 weeks, suggesting strong potential for the drug in the weight loss market.
- Competitive Market Pressure: Despite the promising initial data for ABBV-295, AbbVie faces intense competition in the weight loss market from companies like Eli Lilly, which have several late-stage obesity drugs, indicating that the market will become increasingly crowded before AbbVie can launch its product.
- Core Business Stability: AbbVie's primary therapeutic area remains immunology, with projected sales for Skyrizi and Rinvoq exceeding $31 billion in 2023, significantly surpassing Humira's peak sales, demonstrating the company's robust performance and growth potential in this sector.
- Optimistic Pipeline Outlook: Even if ABBV-295 fails in clinical trials, AbbVie has a deep pipeline of investigational products, including the ongoing ABBV-383 cancer treatment, which is expected to provide significant support for the company's future financial performance and further solidify its leadership in the pharmaceutical industry.
See More
T Rowe Price Equity Income Fund's Q1 2026 Investment Moves
- New Stock Additions: In Q1 2026, T Rowe Price Equity Income Fund added a total of 8 stocks, with AstraZeneca PLC (NYSE:AZN) being the largest addition at 665,000 shares valued at $131.15 million, representing 0.83% of the portfolio, indicating confidence in the biopharmaceutical sector.
- Key Position Increases: The fund increased stakes in 37 stocks, notably Rayonier Inc (NYSE:RYN) with an additional 3,090,285 shares, a 92.64% increase, bringing total holdings to 6,426,000 shares, reflecting optimism in the forestry and real estate markets.
- Complete Exits: The fund completely exited 8 holdings in Q1 2026, including AstraZeneca PLC (NYSE:AZN) and Cummins Inc (NYSE:CMI), resulting in a -0.77% and -0.24% impact on the portfolio respectively, indicating a reassessment of these companies' prospects.
- Significant Reductions: The fund reduced positions in 78 stocks, particularly cutting Accenture PLC (NYSE:ACN) by 216,000 shares, a 53.33% decrease, reflecting a cautious outlook on its future performance, especially as the stock has returned -29.15% over the past three months.
See More
AstraZeneca Seeks Accelerated Approval for Ultomiris
- Clinical Trial Success: AstraZeneca's Ultomiris demonstrated a statistically significant and clinically meaningful reduction in proteinuria at Week 34 in the I CAN Phase III trial for IgAN patients, indicating strong potential for treating rare diseases.
- Patient Recruitment Plan: The global trial aims to enroll nearly 510 IgAN patients to assess Ultomiris as a late-line treatment, with successful preliminary results providing robust support for accelerated approval.
- Safety Assessment: The trial results indicated no new safety signals, and Ultomiris's intravenous therapy showed a tolerability profile consistent with prior data, enhancing its competitive position in the market.
- Future Outlook: AstraZeneca plans to file data with regulatory authorities in key regions while continuing the I CAN trial, with results for another primary endpoint expected at Week 106, demonstrating the company's ongoing commitment to the rare disease sector.
See More
AstraZeneca's Antibody Therapy Achieves Late-Stage Trial Success
- Trial Success: AstraZeneca announced a successful late-stage trial of its antibody therapy tozorakimab in the Phase 3 MIRANDA trial for chronic obstructive pulmonary disease (COPD), significantly reducing the annualized rate of moderate-to-severe exacerbations with both statistical and clinical significance.
- Broad Applicability: The therapy demonstrated efficacy across both former and current smokers, indicating its effectiveness regardless of lung function severity and blood eosinophil counts, thereby enhancing its market potential.
- Study Design: The 52-week study evaluated tozorakimab 300 mg administered biweekly against a placebo, aiming to assess its additional efficacy on top of standard inhaled therapy, further validating its clinical application value.
- Favorable Safety Profile: AstraZeneca noted that tozorakimab was generally well tolerated with a safety profile consistent with prior trials, and plans to submit the results to global regulators and present them at future medical events, facilitating its market introduction.
See More
AstraZeneca's IL-33-targeting Biologic Achieves Success in Phase III Trials
- Clinical Trial Results: AstraZeneca's IL-33-targeting biologic tozorakimab demonstrated significant efficacy in the Phase III MIRANDA trial, showing a meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations, particularly among former smokers, indicating its potential first-in-class status in COPD treatment.
- Patient Recruitment: The MIRANDA trial enrolled 1,454 patients, all of whom received tozorakimab 300mg alongside standard care, with results highlighting the drug's important clinical benefits for patients still experiencing exacerbations, thus addressing a critical need in COPD management.
- Safety Profile: Tozorakimab was generally well tolerated with a favorable safety profile consistent with previous trials, providing strong support for its future regulatory approval and the potential to offer new treatment options for COPD patients.
- Market Potential: With COPD being the third leading cause of death globally, affecting nearly 400 million people, the success of tozorakimab could significantly enhance patient quality of life and further bolster AstraZeneca's leadership position in the respiratory therapeutics market.
See More
Pictet North America Advisors Increases Stake in MercadoLibre
- Share Increase: On April 14, 2026, Pictet North America Advisors SA disclosed an increase of 3,529 shares in MercadoLibre, with an estimated transaction value of $6.81 million, indicating confidence in the company's future growth prospects.
- Stake Growth: Following this purchase, Pictet's stake in MercadoLibre rose to 2.21%, reflecting its emphasis on the company within its portfolio, particularly as MercadoLibre's market capitalization reached $92.87 billion.
- Financial Performance: Despite achieving a 44% revenue growth in 2025, MercadoLibre's net income only increased by 5% due to heightened competition and rising non-performing loans, indicating some profitability pressures.
- Market Outlook: Although facing short-term challenges, MercadoLibre is expected to maintain long-term growth potential due to its market leadership in Latin America and robust revenue growth, suggesting that Pictet's decision to increase its holdings may be based on confidence in this outlook.
See More
AbbVie Ventures into Weight Loss Market with Promising Drug
- Clinical Trial Results: AbbVie's March 9 announcement of ABBV-295's clinical trial results indicates that patients receiving weekly treatment lost an average of 7.75% to 9.79% of their weight over 12 weeks, while those on biweekly or monthly regimens lost between 7.86% and 9.73% over 13 weeks, suggesting strong potential for the drug in the weight loss market.
- Competitive Market Pressure: Despite the promising initial data for ABBV-295, AbbVie faces intense competition in the weight loss market from companies like Eli Lilly, which have several late-stage obesity drugs, indicating that the market will become increasingly crowded before AbbVie can launch its product.
- Core Business Stability: AbbVie's primary therapeutic area remains immunology, with projected sales for Skyrizi and Rinvoq exceeding $31 billion in 2023, significantly surpassing Humira's peak sales, demonstrating the company's robust performance and growth potential in this sector.
- Optimistic Pipeline Outlook: Even if ABBV-295 fails in clinical trials, AbbVie has a deep pipeline of investigational products, including the ongoing ABBV-383 cancer treatment, which is expected to provide significant support for the company's future financial performance and further solidify its leadership in the pharmaceutical industry.
See More
